8-oxa-3-azabicyclo[3.2.1]octane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 8-oxa-3-azabicyclo[3.2.1]octane
• 英文别名: (1R,5R)-8-oxa-3-azabicyclo[3.2.1]octane
• 化学式: C₆H₁₁NO
• 分子量: 113.159
• InChiKey: POOPWPIOIMBTOH-PHDIDXHHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  8-oxa-3-azabicyclo[3.2.1]octane 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 palladium 10% on activated carbon 、 甲酸铵 、 sodium carbonate 、 potassium carbonate 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 、 二甲基亚砜 为溶剂， 反应 2.5h， 生成 5-(4-((4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)phenyl)amino)-1,3,5-triazin-2-yl)-2-fluorobenzonitrile
  参考文献：
  名称：

  TANK-BINDING KINASE INHIBITOR COMPOUNDS

  摘要：

  具有以下化学式（I）的化合物以及它们的使用和制备方法已被披露：

  公开号：

  US20160096827A1

文献信息

• [EN] TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES TRICYCLIQUES EN TANT QU'INHIBITEURS DE PHOSPHO-INOSITIDE 3-KINASE
  申请人：KARUS THERAPEUTICS LTD

  公开号：WO2015121657A1

  公开（公告）日：2015-08-20

  A compound of formula I: (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N-H, N-(C1 -C 10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1 -C 10 alkylene, C2 -C10 alkenylene or C2 -C 10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C 10 alkyl, halogen, fluoro C1 -C10 alkyl, O- C1 -C10 alkyl, NH-C1 -C10 alkyl, S-C1 -C10 alkyl, O- fluoro C1 -C10 alkyl, NH-acyl, NH-C(O)-NH-C1 -C10 alkyl, C(O)-NH-C1 -C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3- kinase enzyme, PI3K-p110δ, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.

  一种具有以下结构式I的化合物：(I)或其药学上可接受的盐，其中：W为O、N-H、N-(C1-C10烷基)或S；每个X独立地为CH或N；R1为含有至少1个来自N或O的杂原子的5至7成员饱和或不饱和、可选择地取代的杂环；R2为LY；每个L为直接键、C1-C10烷基、C2-C10烯基或C2-C10炔基；Y为含有最多4个来自N或O的杂原子的可选择地取代的融合、桥接或螺环非芳香性5-12成员杂环；每个R3独立地为H、C1-C10烷基、卤素、氟代C1-C10烷基、O-C1-C10烷基、NH-C1-C10烷基、S-C1-C10烷基、O-氟代C1-C10烷基、NH-酰基、NH-C(O)-NH-C1-C10烷基、C(O)-NH-C1-C10烷基、芳基或杂芳基，可用作类IA磷脂酰肌醇3-激酶酶、PI3K-p110δ的抑制剂，因此在癌症、免疫和炎症性疾病的治疗中具有潜在用途。
• [EN] COMPOSITIONS COMPRISING TRICYCLIC HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSITIONS COMPRENANT DES COMPOSÉS HÉTÉROCYCLIQUES
  申请人：KARUS THERAPEUTICS LTD

  公开号：WO2017029518A1

  公开（公告）日：2017-02-23

  The invention relates to a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical excipient selected from the group consisting of fillers, binders, disintegrants, glidants and lubricants, wherein the compound according to formula I is represented by:

  这项发明涉及一种药物组合物，包括式I的化合物或其药用可接受盐，以及从填料、粘合剂、分散剂、润滑剂和润滑剂组成的群体中选择的至少一种药用辅料，其中根据式I表示的化合物为：
• [EN] COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT<br/>[FR] COMPOSITIONS COMPRENANT DES INHIBITEURS DE LA PHOSPOINOSITIDE 3-KINASE ET UN SECOND AGENT ANTIPROLIFÉRATIF
  申请人：KARUS THERAPEUTICS LTD

  公开号：WO2017029517A1

  公开（公告）日：2017-02-23

  The invention relates to a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of signal transduction pathway inhibitors, tumour immunotherapeutics, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, proteasome Inhibitors, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors, conventional cytotoxic agents or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors.

  这项发明涉及一种药物组合物，包括化合物(I)或其药学上可接受的盐，以及从信号转导途径抑制剂、肿瘤免疫治疗药物、抑制BCL2蛋白家族的药物、抑制Mcl-1的药物、蛋白酶体抑制剂、聚(ADP核糖)聚合酶(PARP)抑制剂、芳香化酶抑制剂、传统细胞毒药物或从阿比特龙、ARN-509和MYC抑制剂中选择的杂项药物中选择的至少一种第二药剂。
• TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS
  申请人：KARUS THERAPEUTICS LTD

  公开号：US20160347771A1

  公开（公告）日：2016-12-01

  A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C 1 -C 10 alkyl) or S; each X is independently CH or N; R 1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R 2 is LY; each L is a direct bond, C 1 -C 10 alkylene, C 2 -C 10 alkenylene or C 2 -C 10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R 3 is independently H, C 1 -C 10 alkyl, halogen, fluoro C 1 -C 10 alkyl, O—C 1 -C 10 alkyl, NH—C 1 -C 10 alkyl, S—C 1 -C 10 alkyl, O-fluoro C 1 -C 10 alkyl, NH-acyl, NH—C(O)—NH—C 1 -C 10 alkyl, C(O)—NH—C 1 -C 10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110δ, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.
• TANK-BINDING KINASE INHIBITOR COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160096827A1

  公开（公告）日：2016-04-07

  Compounds having the following formula (I) and methods of their use and preparation are disclosed:

  具有以下化学式（I）的化合物以及它们的使用和制备方法已被披露：